Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 6Head & Neck 2Thoracic 1Gynecologic 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Neuroendocrine Tumors 34Pheochromocytoma 14Thyroid Neoplasms 11Pituitary Neoplasms 11Carcinoma, Neuroendocrine 10Adrenocortical Carcinoma 10Thyroid Cancer, Papillary 9Paraganglioma 8Sarcoma 7Adrenal Gland Neoplasms 7Small Cell Lung Carcinoma 6Neuroblastoma 6Cushing Syndrome 6Parathyroid Neoplasms 5Neoplasms 5Carcinoma, Medullary 5Carcinoid Tumor 5Pancreatic Neoplasms 4Ovarian Neoplasms 4Osteosarcoma 4Multiple Endocrine Neoplasia Type 1 4Meningioma 4Insulinoma 4Cholangiocarcinoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Carcinoma, Hepatocellular 4Adenoma, Islet Cell 4Adenocarcinoma, Follicular 4Thyroid Carcinoma, Anaplastic 3

Interventions

fludarabine 1aldesleukin 1Nivolumab 1Ipilimumab 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × Endocrine × 30 days × Clear all
NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡